UCAD 2017 will be held in the Grand Ballroom which is situated on the lobby level of Rydges World Square.
The exhibition will be held in Ballroom 1 with the plenary conveniently located next door in Ballrooms 2 & 3.
The exhibition space, which features natural light, will be where all catering including stand up working lunches and coffee cart will be located. Free Wi-Fi for all meeting delegates and sponsors is included.
Sponsorship opportunities are still available for this meeting. For further information about how your organisation can be involved as a partner in this meeting please contact [email protected] for a prospectus.
As a global leader in medical technology, services and solutions, Medtronic improves the health and lives of millions of people each year. We believe our deep clinical, therapeutic and economic expertise can help address the complex challenges — such as rising costs, aging populations, and the burden of chronic disease — faced by families and healthcare systems today. But, we can’t do it alone. That’s why we’re committed to partnering in new ways and developing powerful solutions that deliver better patient outcomes.
Founded in 1949 as a medical repair company, we’re now among the world’s largest medical technology, services and solutions companies, employing more than 85,000 people worldwide, serving physicians, hospitals and patients in more than 160 countries.
Join us in our commitment to take healthcare Further, Together. Learn more at Medtronic.com.au.
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. We now offer the most comprehensive set of solutions, including products and technologies in coronary, cardiac rhythm management, electrophysiology, heart failure, structural heart, vascular and endovascular. Our breadth and depth of industry-leading technologies, along with our combined team of experts, bring you end to end solutions and services. This means better care and a greater variety of contracting options exclusively focused on delivering increased value and efficiencies for our customers. Abbott serves people in more than 150 countries and employs approximately 74,000 people.
Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.
BIOTRONIK is a privately owned, global medical device company, with products and services that save and improve the quality of life for patients suffering from cardiovascular and endovascular diseases. Our research and development of cardiovascular medical devices exemplifies our commitment to maximum safety and top quality. Our Cardiac Rhythm Management (CRM) portfolio comprises of implantable pacemakers and defibrillators, leads, accessories and external devices to treat and manage arrhythmia-related diseases.
At Boehringer Ingelheim our purpose is simply to ‘Make More Health’ – for patients, our people and our community. For 130 years we have remained a family-owned, independent company and today operate globally employing more than 50, 000 people.
We practice excellence, innovation and value in the discovery of new medicines and are committed to operating as an ethical and sustainable company. We constantly seek new and better ways to treat diseases in people and animals.
Boston Scientific is dedicated to advancing science for life and has supported patients and HCPs in Australia and New Zealand since 1995. Boston Scientific Rhythm Management is proud to offer solutions from the core CRM portfolio to our most innovative products including Emblem™ MRI S-ICD System, Rhythmia™ 3D Mapping System, Accolade™ MRI Pacemaker System, and Watchman™ LAAC Device. Our technologies are complimented by clinical excellence and dedicated HCP support in improving patients’ lives. We are proud to once again support the UCAD meeting.
About the Bristol-Myers Squibb/Pfizer Collaboration: In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb (registered as ELIQUIS® and indicated in Australia for stroke prevention in non valvular atrial fibrillation and the treatment and prevention of recurrence of venous thromboembolic (VTE) events in adult patients). This global alliance combines Bristol-Myers Squibb’s long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise in this field.